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INTRODUCTION
Gastrointestinal stromal tumor (GIST) is a mesenchymal
tumor of the digestive tract showing lineage differentiation
similar to the interstitial cell of Cajal (ICC) and accounts for
about 2% of all GI tract neoplasms (1). Their morphology
varies from undifferentiated to differentiated tumors having
myoid or neural differentiation. So, various kind of diagnos-
ing methods including immunohistochemical stains and
electron microscopy were established. And also recent rapid
progress has been accomplished for the molecular genetics
of GISTs, and studies on the molecular-based classification
of GISTs are underway (2). 
c-kit (CD117) is a transmembrane tyrosine kinase receptor
and its expression appears to play a key role in committing
the primitive mesenchymal cells towards ICC differentia-
tion. Some GISTs contain activating mutations in the kit
proto-oncogene and this is associated with the expression of
the c-kit protein (3). The identification of the mutations that
are mostly in exon 11 and to a lesser extent in exons 9 and
13 of the kit proto-oncogene coding for c-kit in many GISTs
has resulted in a better understanding of their oncogenic mech-
anisms. The true neural and smooth muscle neoplasms of the
GI tract entirely lack these kit mutations (4). So, c-kit expres-
sion has been proposed as being the most sensitive and spe-
cific phenotypic marker of GISTs. Although 90% of GISTs
were found to be immunohistochemically positive for c-kit
(5-12), and the mutations of kit gene have been found in 80%
to 85% of these c-kit positive GISTs, a minority of GISTs
lack any kit mutations, but nonetheless, c-kit is strongly acti-
vated (2, 4, 8). Such GISTs might contain kit mutations that
are not readily detected by the conventional screening meth-
ods, or alternately, the c-kit might be activated by nonmuta-
tional mechanisms. Moreover, in 35% of the GISTs lacking
the kit mutations, intragenic mutations in the related recep-
tor for tyrosine kinase, platelet-derived growth factor recep-
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Gastrointestinal Stromal Tumors in Koreans: It's Incidence and the
Clinical, Pathologic and Immunohistochemical Findings
Seven hundred forty seven cases of gastrointestinal stromal tumors (GISTs) in
Koreans who were diagnosed between 2001 and 2002 were analyzed to evaluate
their occurrence and their clinical, pathologic and immunohistochemical findings.
The most frequent location of tumor was in the stomach (63%), followed by the
small intestine (30%), the colorectum (5%), and the esophagus (2%). c-kit expres-
sion was found in 93.6% of the cases, while CD34, SMA and S-100 protein was
positive in 80.1%, 28.2%, and 20.2%, respectively. c-kit positivity was high in the
stomach (94.2%) and small intestine (94.6%), while it was relatively low in the col-
orectum (85.0%), and esophagus (81.2%). The positivity for CD34 was correlated
with the higher risk of GISTs (p=0.04). Follow up of the patients showed that 58
primary GISTs patients died and 20 of these patients were recurrent or metastatic
at the time of diagnosis. The pathologic diagnosis to predict the risk of aggressive
behavior of GISTs was correlated with the numbers of tumor, clinical stage, epithe-
lioid histologic type, cellularity, cellular atypia, necrosis, and mucosal invasion (p=
0.00). GISTs with a poor prognosis were closely related to the clinical stage at pre-
sentation, the locations of the tumor, and the ages of the patients.
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tor alpha (PDGFRA), have recently been reported (13, 14).
Therefore, the current definition of GISTs as c-kit positive
mesenchymal tumors of uncertain malignant potential fails
to include a number of GIST cases that have similar histolo-
gy. Although confirmatory c-kit staining is required for drug
therapy and approximately 95% of GISTs stain positively
for c-kit (15), the most important tool needed to diagnose
GIST is still hematoxylin and eosin-stained section (16), and
this will encompass the PDGFRA mutation-positive and c-
kit-negative GISTs, both the PDGFRA and kit mutation-
negative GISTs, and the rare kit mutation-positive and c-kit-
negative GISTs (2).
Immunohistochemical stainings for the other markers are
more variable; these include CD34 (47-100%), muscle spe-
cific actin (0-50%, usually focal staining), S-100 protein (5-
30%), and desmin (2-5%) (15-17). Despite the recent remar-
kable progress in understanding and treating GISTs, patholo-
gists still have difficulty for predicting behavior of GISTs.
Of those GISTs that undergo resection, about half of the cases
have possibility of recurrence or metastasis (18). Although a
large tumor size and high mitotic activity have been strong-
ly associated with malignancy (17), it can not completely
exclude their malignant potential in tumors with small size
and no mitosis (19). 
However, in Korea, the incidence and the clinicopatho-
logic features of GISTs have not been characterized because
most of the previous studies have been mainly focused on one
institution’s experience (20-24), and the multi-institutional
studies were focused on the stomach (25, 26). In an attempt
to survey the approximate incidence, clinicopathologic char-
acteristics and immunophenotypic features of GISTs in Kore-
an, we conducted a clinicopathologic and immunohistochemi-
cal analysis of 747 mesenchymal tumors that had the histo-
logic features of GIST.
MATERIAL AND METHODS
Tissue samples were obtained from Korean patients who
had mesenchymal tumors of the gastrointestinal tract. The
patients who met the following criteria were selected for
study; 1) they were operated or biopsied from 1 January
2001 to 31 December 2002; 2) the clinical information for
this clinicopathologic study was available; 3) the patients
could be followed up after the surgery or biopsy. Paraffin blocks
of the GISTs were taken from 50 major hospitals in Korea
including 40 university hospitals. The data sheets including
the operation titles, the organ site of involvement, sizes of
the tumors, number of the tumors, clinical or pathologic stag-
ing, histopathologic tumor types, mitotic counts, presence
of cellular pleomorphism, benign cellular patterns, necrosis
and mucosal invasion, were distributed to all participating
centers of this study. All available H&E stained slides were
reviewed and the important pathologic findings were care-
fully checked and described in each case. The diagnostic cri-
teria for the malignant behavior of GISTs were assessed by
the criteria of the NIH GIST workshop (Table 1) (17).
Immunohistochemical staining was performed with using
primary antibodies including rabbit polyclonal anti-human
c-kit (Dako, 1:400), CD34 (clone Qbend10, Dako, 1:50),
alpha-smooth muscle actin (SMA) (clone 1A4, Dako, 1:50),
and S-100 protein (polyclonal, Dako, 1:1,000) and with using
a DAKO EnVisionTM+System according to the manufacturer's
instructions. Diaminobenzidine (DAB) was used as a chro-
mogen. Boiling the slides in the citrate buffer for 10 min was
performed with microwaves for antigen retrieval of the c-kit
and CD34. The GISTs were selected on the basis of their histo-
pathologic features and the immunohistochemical staining
results for c-kit, CD34, SMA and S-100. The diagnostic cri-
teria are summarized in Table 2. Briefly, all the mesenchymal
tumors with c-kit positivity were diagnosed as GISTs, and
the c-kit -negative and CD34-positive cases or all the immu-
nomarker-negative cases having the histopathologic features
of GISTs were diagnosed as ‘‘consistent with’’ GISTs. Accord-
ing to the immunophenotypic features, the tumors were clas-
sified into four types by using Rudolph et al. classification
with slight modification (16): a) gastrointestinal fibrous tumors
(GIFT), which were vimentin and/or CD34 positive with-
out smooth muscle or neural differentiation; b) GISTs with
smooth muscle differentiation that were SMA positive (GILT);
c) GISTs with neural differentiation that were S-100 protein-
positive (GINT); and d) GISTs with dual smooth muscle and
neural differentiation (GIDT). The collected data were ana-
lyzed using SPSS software and by employing  2 and Kruskal- Proposed approach for defining risk of aggressive behavior in GISTs
(by NIH Consensus Meeting, Hum Pathol 33:459-465, 2002)
Size Mitotic count
Very low risk <2 cm <5/50 HPF
Low risk 2-5 cm <5/50 HPF
Intermediate risk <5 cm 6-10/50 HPF
5-10 cm <5/50 HPF
High risk >5 cm >5/50 HPF
>10 cm Any mitotic rate
Any size >10/50 HPF
Table 1. Diagnosis of GIST malignancy based on tumor size
and mitosis
KIT (CD117) CD34 SMA S-100
GIST, by definition + + or - + or - + or -
(47-100%) (0-50%) (5-30%)
GIST-like tumors - + + or - + or -
-- - -
Smooth muscle tumor -- + rare (+)
Schwannoma -- - +
Table 2. Immunohistochemical findings used in the diagnosis
of GISTs
HPF, High power field.Gastrointestinal Stromal Tumors in Koreans 979
Wallis tests and Pearson’s correlation coefficient.
RESULTS
Clinical findings
Seven hundred forty seven GISTs were diagnosed among
the 849 gastrointestinal mesenchymal tumors that occurred
from 2001 to 2002 (334 in 2001 and 413 in 2002). The
male to female ratio was 374 to 373. The patients with GISTs
ranged in age from 10 to 87 yr (mean 56.3 yr) and the peak
age was between 50 and 70 (Fig. 1). According to the oper-
ation method, wide resection and excision were performed
in 541 cases (71%), and wedge resection or biopsy were per-
formed in 247 cases (20%); and 59 cases (8%) were found
incidentally. All incidentally found GISTs were single tumors
with sizes ranging from 0.2 cm to 9.5 cm, and most of them
were less than 2.0 cm with the mean size being 1.2 cm. They
were found during operations for gastric carcinoma in 54
cases, esophageal carcinoma in 2 cases, colon carcinoma in 2
cases and ovarian carcinoma in 1 case. 
The sizes of the mass varied from 0.2 cm to 53 cm with
the mean size being 6.1 cm (Fig. 2). The most frequent loca-
tion of the GISTs was in the stomach, followed by the small
intestine and the colorectum (Fig. 3). In 11 cases, multiple
tumor masses were found after metastatic or recurrent tumor
nodules had been excluded. Among these multiple GISTs,
eight cases occurred in the small intestine and one case was
associated with neurofibromatosis. 
The clinical stages of the disease are described in Fig. 4.
We found three cases of GIST showing the regional lymph
nodes metastasis at the time of operation. These three cases
were all male patients. The tumor displayed a high risk of
malignant behavior, the mean tumor size was 12.5 cm and
the tumors occurred in the small intestine, rectum and stom-
ach, respectively. Although these three cases showed metas-
tasis and recurrent tumor during the follow up, the patients
are still alive at more than 36 months after chemotherapy.
The patients’ survival status was followed up for 12-36
months by using the data obtained from the Korea National
Statistical Office. Seventy one patients had died by Decem-
ber 31, 2003, and 13 of them had incidentally found GISTs
during their operations for disease other than the GISTs. Of
the remaining 58 primary GISTs, the small intestine and
the stomach were the most common locations with 28 and
25 cases, respectively, while the colorectum and the esopha-
gus comprised the remaining 5 cases. Among 58 patients
who died of GISTs, 20 of them showed recurrent or metastatic
tumor nodules at the time of diagnosis. Their pathologic
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Fig. 1. Distribution of the ages of the patients with gastrointestinal
stromal tumors in 747 patients.
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Fig. 3. Anatomic locations of the gastrointestinal stromal tumors.
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Fig. 4. Clinical stages of the patients at the time of diagnosis.
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Fig. 2. Distribution of the sizes of the gastrointestinal stromal tumors.980 K.-M. Kim, D.W. Kang, W.S. Moon, et al.
Fig. 5. Photograph of the representative findings of gastrointestinal stromal tumors. (A) Epithelioid type GIST. (B) Spindle cell type GIST.
(C) Mixed epithelioid and spindle cell type GIST. (D) hyaline changes observed in GIST. (E) Myxoid changed observes in GIST. (F) Ischemic
tumor necrosis observed in GIST. (G) Mucosal invasion observed in the small intestinal mucosa. (H) Skeinoid fibers observed in the small
intestinal GIST. (I) Paraganglioma-like patterns observed in the small intestinal GIST. 
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Idiagnosis included 50 high risk tumors, 4 intermediate risk
tumors and 4 low risk tumors. Forty nine (84.5%) of the 58
cases showed c-kit protein expression. In this study, progno-
sis of the GISTs were closely related to the clinical stages at
presentation, pathologic diagnosis of GISTs, and the loca-
tions (p<0.05). 
The breakdown of the low risk GISTs patients having a
poor prognosis showed 2 small intestinal, 1 esophageal and
1 rectal tumor location with the patients’ ages being over
65 yr; there were multiple tumors in 2 cases and diffuse cyto-
plasmic staining for c-kit protein in 3 cases. 
Histopathologic findings
Of the total 849 cases of mesenchymal tumors of the gas-
trointestinal tract, 747 cases were diagnosed as GISTs includ-
ing 48 GIST-like tumors that met the criteria described in
the materials and methods section. When all the GISTs were
classified according to the pathologic factors that define the
risk of aggressive behavior in GISTs, very low risk, low risk,
intermediate risk and high risk were found in 112 (13.6%),
216 (29.1%), 159 (21.4%), and 255 (34.4%) cases, respec-
tively. The increasing aggressive risk of GISTs was correlat-
ed with increased number of tumors, higher clinical stage,
epithelioid histology, high cellularity, severe cellular atypia,
the presence of necrosis, and mucosal invasion (p=0.00). 
For histology, spindle cell type was found in 578 cases (77.4
%) (Fig. 5A), epithelioid cell type was found in 66 cases (8.8
%) (Fig. 5B), and mixed type was found in 103 cases (13.8%)
(Fig. 5C). Benign cellular patterns such as hyaline changes
(Fig. 5D), cystic changes and myxoid changes (Fig. 5E) were
observed in 267 cases, which included 46 cases of very low
risk, 97 cases of low risk, 48 cases of intermediate risk and
76 cases of high risk. The benign cellular pattern was inversely
correlated with the risk level of the GISTs (p=0.007). Necrosis
(Fig. 5F) was found in 215 cases, of which 2 cases were very
low risk, 24 cases were low risk, 38 cases were intermediate
risk and 151 cases were high risk. The low risk group show-
ing necrosis exhibited sizes around 5 cm and mitotic figures
close to 5/50HPF. Mucosal invasion (Fig. 5G) was found in
149 cases; there were 2 cases of very low risk, 26 cases of low
risk, 34 cases of intermediate risk, and 87 cases of high risk.
Dystrophic calcification was found in 2 cases of GISTs with
low and very low risk of malignant potential, respectively.
Skeinoid fibers (Fig. 5H) were almost exclusively found in
the small intestinal GISTs. Paraganglioma-like histologic
features were observed in five cases of small intestinal GISTs
as well as 8 gastric GISTs of the mixed spindle and epithelioid
histologic types (Fig. 5I). These paraganglioma-like features
were apparent in the superficial areas of the mass that possessed
plump vascular structures. 
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Fig. 6. c-kit expression according to the pathologic diagnosis defin-
ing the risk of aggressive behavior for the gastrointestinal stromal
tumors.
Negative
Stomach Colorectum Esophagus Total
Small
intestine
GIFT 336 80 24 4 444
(72%) (36%) (60%) (25%) (59%)
GILT 66 68 10 7 151
(14%) (30%) (25%) (44%) (20%)
GINT 52 35 5 1 93
(11%) (16%) (12%) (6%) (13%)
GIDT 15 39 1 4 59
(3%) (18%) (3%) (25%) (8%)
Total 469 222 40 16 747
(100%) (100%) (100%) (100%) (100%)
Table 4. Relationship between organ site and classification of
GISTs according to differentiation
GIFT, Gastrointestinal stromal tumor with fibroblastic differentiation; GINT,
Gastrointestinal stromal tumor with neural differentiation; GILT, Gastroin-
testinal stromal tumor with smooth muscle differentiation; GIDT, Gastroin-
testinal stromal tumor with dual smooth muscle and neural differentia-
tion.
C-kit
positive negative
CD34
positive negative
SMA
positive negative
S-100
positive negative
GIST 699 0 571 125 203 493 141 556
(100.0%) (0.0%) (82.0%) (18.0%) (29.2%) (70.8%) (20.2%) (79.8%)
GIST-like Tumor 0 48 26 22 6 42 12 36
(0.0%) (100.0%) (54.2%) (45.8%) (12.5%) (87.5%) (25.0%) (75.0%)
Total 699 48 597 147 209 535 153 592
(93.6%) (6.4%) (80.2%) (19.8%) (28.1%) (71.9%) (20.5%) (79.5%)
Table 3. Immunohistochemical staining results in GISTs
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Of the 747 GISTs, c-kit expression was found in 699 cases
(93.6%) and its expression, according to the histologic diag-
nosis, for defining the risk of aggressive behavior is depicted
in Fig. 6. c-kit was positive in 90.2% of very low risk, 94.0%
of low risk, 93.7% of intermediate risk, and 95.3% of high
risk GISTs (p>0.05). The c-kit expression was noted to be
diffuse in the cytoplasm and along the cytoplasmic mem-
brane of the tumor cells; in 24 cases, a dot-like c-kit expres-
sion was predominant rather than the membranous staining.
Focal c-kit expression was observed in a total of 34 cases with
cytoplasmic (29 cases) and a dot-like pattern (5 cases). In most
of these cases, the pathologic diagnoses were very low and
low risk of malignant potential and their histologic types
were spindle cell type in 20 cases, epithelioid cell type in 5
cases, and mixed cell type in 5 cases.
CD34, SMA and S-100 protein were positive in 597 (80.2
%), 209 (28.1%), and 153 (20.5%) cases, respectively (Table
3). The GISTs with c-kit expression were related with CD34
positivity and with high cellularity of GISTs (p<0.05). But
patients’ gender, age, resection range, size of tumor, clinical
stage, histologic type, presence of benign cellular pattern,
necrosis and expression of S-100 protein were not related
with the c-kit expression status (p>0.05). According to the
locations of GISTs, c-kit positivity was high in the stomach
(94.2%) and the small intestine (94.6%), while it was rela-
tively low in the colorectum (85.0%), and the esophagus
(81.2%). Additionally, all three cases with lymph node metas-
tasis showed diffuse c-kit staining. 
When dividing the GISTs according to their differentia-
tion based on the immunophenotypic features, GIFT was the
most common type (59.4%), followed by GILT (20.2%),
GINT (12.5%), and GIDT (7.9%), respectively (Table 4).
Fibroblastic differentiation (GIFT) was most frequent in the
highly cellular and epithelioid GISTs, and it was more preva-
lent in the stomach and colorectum. Neural differentiation
(GINT) was common in the small intestine, while smooth
muscle differentiation (GILT) was common in the esophagus
(Table 4).
DISCUSSION
Although several papers describing the clinicopathologic
characteristics (20-22, 25, 26), the genetic (23, 24), and ultra-
structural findings (27) of GISTs in Koreans have been report-
ed, this multi-institutional study provides much more infor-
mation on the clinical and immunophenotypic characteris-
tics of GISTs in Koreans. In this study, we found that small
intestinal GISTs were more common while colorectal and
esophageal GISTs were less frequent in Koreans than in the
Western countries (9, 17, 18). Like the previous reports sug-
gesting the aggressive behavior of small intestinal GISTs,
our survival data showed that the small intestinal GISTs com-
prised the most common cause of death by GISTs, although
they made up only 30% of the total GISTs.
It is known that the epithelioid GISTs, which are the same
as leiomyoblastomas of Stout, comprise about 10% of the
gastric GISTs (9). In our series, 50 out of the 470 gastric
GISTs (10.6%) were of epithelioid type. The spindle cell type
was more frequent than epithelioid type and these results
are in good agreement with the previous data (1, 5, 17). 
In immunohistochemistry, c-kit was positive in 81-100%
of the GISTs arising in the esophagus, stomach, small intes-
tine and colon. The GISTs with either spindle cell or epithe-
lioid type were both positive for c-kit, though the staining
was less intense in the latter. The predominant membranous
staining that can be observed in fibroblasts or myofibroblasts
with the rabbit polyclonal antibody manufactured by Dako
(28) was not observed in any of the cases we examined. CD34
was positive in 47-100% of the GISTs and its expression var-
ied with the location of the tumor within the gastrointesti-
nal tract. Miettinen et al. (10) found that among the c-kit
positive tumors that they studied, 100%, 90%, 47%, 65%,
96% and 64% of the cases were CD34 positive in the esoph-
agus, stomach, small intestine, colon, rectum and extrain-
testinal locations, respectively. In this study, CD34 expres-
sions were 90%, 78%, 63% and 62% of the cases in the stom-
ach, colorectum, small intestine and esophagus, respectively.
Although CD34 positivity in the stomach was the same as
that of previous study, its expression was somewhat different
in the esophagus and small intestine. There have been some
reports that CD34 is, perhaps, more often negative in malig-
nant GISTs (29), although the opposite was found by Wang
et al. (30). In our study, CD34 expression was positively cor-
related with the higher risk of malignancy in GISTs and this
result may have been caused by higher positivity of CD34
in the small intestine and the lower CD34 expression in the
esophagus. SMA was found only focally in 0-47% of the total
cases and its expression rate was inversely correlated to that
of CD34 (15-19). In our study, SMA was positive in 28.1%
of the cases and it was most frequently expressed in the eso-
phageal GISTs. Moreover, SMA expression was inversely cor-
related with the higher risk of malignancy in GISTs. How-
ever, the expression of S-100 protein in this study was higher
than in the previous western studies, which were reported
to be less than 10% of the cases with S-100 protein expres-
sion (1, 5, 17), and our findings were correlated well with
the previous Korean reports (20). In the previous reports, the
S-100 protein expression in GISTs was different according
to the location of the tumor; it was more frequently expressed
in the small intestinal GISTs (12, 31), and it was rarely ex-
pressed in the large intestine (11). The possible reasons for
this high positivity may have been the higher incidence of
small intestinal GISTs (20% vs. 30%), the lower incidence
of colorectal GISTs (10% vs. 5%), the higher percentage of
multiple and malignant GISTs in Koreans, and the differ-
982 K.-M. Kim, D.W. Kang, W.S. Moon, et al.ences in the interpretation of the results. 
With this study, we found that expressions of CD34 and
SMA were positively and inversely correlated with the higher
risk of malignant potential in GISTs. The focal positivity of
c-kit was associated with lower risk of malignant potential.
According to the immunophenotypic features, GIFTs were
common in the stomach and the colon. GILTs were common
in the esophagus and GINTs were common in the small
intestine. The higher incidence of GISTs with high risk of
malignant potential and the more frequent small intestinal
GISTs in Korean resulted in a higher death rate. 
For further study, we need to continue with a) following
up on these patients and completing the clinical data on
recurrence, metastasis and survival, b) detecting the histo-
logic and immunohistochemical markers that correlate with
the prognosis, and c) performing genetic studies of kit and
PDGFRA using kit-negative and multiple GISTs.
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